JOP20200005B1 - تركيبات صيدلية - Google Patents

تركيبات صيدلية

Info

Publication number
JOP20200005B1
JOP20200005B1 JOJO/P/2020/0005A JOP20200005A JOP20200005B1 JO P20200005 B1 JOP20200005 B1 JO P20200005B1 JO P20200005 A JOP20200005 A JO P20200005A JO P20200005 B1 JOP20200005 B1 JO P20200005B1
Authority
JO
Jordan
Prior art keywords
pharmaceutical formulations
valsartan
atorvastatin
metformin
formulation
Prior art date
Application number
JOJO/P/2020/0005A
Other languages
English (en)
Inventor
Matthew Carl Allgeier
Tony Yantao Zhang
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of JOP20200005A1 publication Critical patent/JOP20200005A1/ar
Application granted granted Critical
Publication of JOP20200005B1 publication Critical patent/JOP20200005B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

يتعلق الاختراع الحالي بتركيبات ذات جرعة ثابتة فموية صلبة من ميتفورمين، وأتور?استاتين، و?السارتان، أو أملاح مقبولة صيدليًا منها، وعمليات لتحضيرها، واستخدام التركيبة لعلاج أمراض محددة.
JOJO/P/2020/0005A 2017-07-17 2020-01-14 تركيبات صيدلية JOP20200005B1 (ar)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762533332P 2017-07-17 2017-07-17
US201762538936P 2017-07-31 2017-07-31
PCT/US2018/041378 WO2019018155A1 (en) 2017-07-17 2018-07-10 PHARMACEUTICAL COMPOSITIONS

Publications (2)

Publication Number Publication Date
JOP20200005A1 JOP20200005A1 (ar) 2020-01-14
JOP20200005B1 true JOP20200005B1 (ar) 2024-04-18

Family

ID=63036446

Family Applications (2)

Application Number Title Priority Date Filing Date
JOJO/P/2020/0005A JOP20200005B1 (ar) 2017-07-17 2020-01-14 تركيبات صيدلية
JOJO/P/2023/0099A JOP20230099A1 (ar) 2017-07-17 2023-05-04 تركيبات صيدلية

Family Applications After (1)

Application Number Title Priority Date Filing Date
JOJO/P/2023/0099A JOP20230099A1 (ar) 2017-07-17 2023-05-04 تركيبات صيدلية

Country Status (25)

Country Link
US (2) US11376223B2 (ar)
EP (1) EP3654955B1 (ar)
JP (1) JP6854384B2 (ar)
KR (1) KR102409102B1 (ar)
CN (1) CN110913843B (ar)
AU (1) AU2018301924B2 (ar)
BR (1) BR112019028278A2 (ar)
CA (1) CA3069948C (ar)
CL (1) CL2020000120A1 (ar)
CO (1) CO2019015099A2 (ar)
CR (1) CR20190577A (ar)
DO (1) DOP2020000010A (ar)
EC (1) ECSP20003493A (ar)
ES (1) ES3032318T3 (ar)
IL (1) IL272044A (ar)
JO (2) JOP20200005B1 (ar)
MA (1) MA49625A (ar)
MY (1) MY198062A (ar)
PE (1) PE20200174A1 (ar)
PH (1) PH12020500120A1 (ar)
SA (1) SA520410976B1 (ar)
SG (1) SG11201912482WA (ar)
UA (1) UA125535C2 (ar)
WO (1) WO2019018155A1 (ar)
ZA (1) ZA201908550B (ar)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019028278A2 (pt) * 2017-07-17 2020-07-14 Eli Lilly And Company composições farmacêuticas

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2290624C (en) 1997-06-06 2006-12-05 John W. Shell Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
EP1063973B1 (en) 1998-03-19 2016-11-16 Bristol-Myers Squibb Company Biphasic controlled release delivery system for high solubility pharmaceuticals and method
AR033390A1 (es) * 2000-08-22 2003-12-17 Novartis Ag Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US8329217B2 (en) * 2001-11-06 2012-12-11 Osmotica Kereskedelmi Es Szolgaltato Kft Dual controlled release dosage form
CN1688341A (zh) * 2002-08-08 2005-10-26 三共株式会社 降低血脂的药物组合物
US20050013863A1 (en) * 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
PL2120878T3 (pl) 2007-02-09 2015-01-30 Alphapharm Pty Ltd Postać dawkowania zawierająca dwa czynne składniki farmaceutyczne o różnych postaciach fizycznych
WO2008146178A2 (en) * 2007-05-30 2008-12-04 Wockhardt Research Centre A novel tablet dosage form
US9056134B2 (en) 2010-07-21 2015-06-16 Nucitec S.A. De C.V. Single daily dosage form for prevention and treatment of metabolic syndrome
US9572784B2 (en) * 2011-01-07 2017-02-21 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
IN2014MN01919A (ar) * 2012-03-30 2015-07-10 Dae Woong Pharma
KR20140028971A (ko) * 2012-08-31 2014-03-10 한미약품 주식회사 아토바스타틴, 이르베살탄 및 탄산마그네슘을 포함하는 이층정 복합제제
CN103054856A (zh) * 2012-12-30 2013-04-24 成都恒瑞制药有限公司 含有盐酸二甲双胍和阿托伐他汀钙的固体口服制剂
KR101597004B1 (ko) * 2013-07-25 2016-02-23 씨제이헬스케어 주식회사 서방형 메트포르민과 속방형 HMG-CoA 환원효소 억제제를 포함하는 복합제제
BR102013028883A2 (pt) 2013-11-08 2015-10-06 Hypermarcas S A forma farmacêutica oral para a prevenção de doenças vasculares, comprimido como forma farmacêutica e cápsula gelatinosa como forma farmacêutica
US20160067217A1 (en) * 2014-09-09 2016-03-10 ARKAY Therapeutics, LLC Metabolic syndrome treatment
BR112019028278A2 (pt) * 2017-07-17 2020-07-14 Eli Lilly And Company composições farmacêuticas

Also Published As

Publication number Publication date
EP3654955C0 (en) 2025-05-07
EP3654955A1 (en) 2020-05-27
US20220287978A1 (en) 2022-09-15
ZA201908550B (en) 2024-06-26
CA3069948A1 (en) 2019-01-24
WO2019018155A1 (en) 2019-01-24
ES3032318T3 (en) 2025-07-17
SG11201912482WA (en) 2020-02-27
EP3654955B1 (en) 2025-05-07
ECSP20003493A (es) 2020-08-31
DOP2020000010A (es) 2020-02-28
MY198062A (en) 2023-07-31
US11918692B2 (en) 2024-03-05
PH12020500120A1 (en) 2020-09-28
CN110913843B (zh) 2022-09-13
IL272044A (en) 2020-03-31
CR20190577A (es) 2020-01-29
JP6854384B2 (ja) 2021-04-07
NZ760868A (en) 2023-09-29
CA3069948C (en) 2022-05-17
JOP20230099A1 (ar) 2023-05-04
MA49625A (fr) 2020-05-27
SA520410976B1 (ar) 2023-03-23
JP2020527147A (ja) 2020-09-03
AU2018301924B2 (en) 2021-07-29
BR112019028278A2 (pt) 2020-07-14
US11376223B2 (en) 2022-07-05
AU2018301924A1 (en) 2019-12-19
US20210137842A1 (en) 2021-05-13
UA125535C2 (uk) 2022-04-13
CL2020000120A1 (es) 2020-07-17
PE20200174A1 (es) 2020-01-24
JOP20200005A1 (ar) 2020-01-14
KR102409102B1 (ko) 2022-06-16
CO2019015099A2 (es) 2020-01-17
KR20200015758A (ko) 2020-02-12
CN110913843A (zh) 2020-03-24

Similar Documents

Publication Publication Date Title
MX2021004110A (es) Composiciones farmaceuticas que comprenden n-(3,5- dimetoxifenil)-n'-(1-metiletil)-n-[3-(1-metil-1h- pirazol-4-il)quinoxalin-6-il]etano-1,2-diamina.
EA201892395A1 (ru) Лекарственные составы ингибитора lsd1
CY1125488T1 (el) Παραγωγα πυριδινης και θεραπευτικες χρησεις αυτων ως αναστολεις trpc6
CL2018001199A1 (es) Composiciones terapéuticas para el tratamiento del virus de inmunodeficiencia humana
EA201992116A1 (ru) Фармацевтические составы флороглюцинола и триметилфлороглюцинола
MX387731B (es) Composiciones farmacéuticas orales de mesalazina.
CR20160529A (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
EA201692298A1 (ru) Производные карбоксамидов
WO2016006974A3 (en) Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
WO2016006975A3 (en) Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof
EA201991286A1 (ru) Твердая фармацевтическая композиция для перорального применения, содержащая тенофовир и эмтрицитабин
MX381932B (es) Composicion intranasal que comprende betahistina.
JOP20200005B1 (ar) تركيبات صيدلية
MX2019009909A (es) Composiciones farmaceuticas para terapia de combinacion.
EA201790020A1 (ru) Соединения, фармацевтические композиции и их применение при лечении нейродегенеративных заболеваний
MX384394B (es) Compuesto para uso en la prevención y tratamiento de enfermedades neurodegenerativas.
EA201992754A1 (ru) Фармацевтические композиции
MX375329B (es) 2,2,2-trifluoroetil-tiadiazinas.
EA201791798A1 (ru) Фармацевтические композиции, включающие n-(3,5-диметоксифенил)-n'-(1-метилэтил)-n-[3-(1-метил-1h-пиразол-4-ил)хиноксалин-6-ил]этан-1,2-диамин
HK1233927A1 (en) Pharmaceutical formulations of a pan-raf kinase inhibitor, processes for their preparation, and methods of use
CU20180036A7 (es) Composiciones terapéuticas para el tratamiento del virus de la inmunodeficiencia humana
MX388249B (es) Composición farmacéutica de desloratadina para ser administrada por vía oral, para el tratamiento de enfermedades relacionadas con la histamina.